An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Sudden cardiac arrest (SCA) in healthy young individuals is a growing concern, with research from the NIH identifying key ...

Anderson Diagnostics is bringing its diagnostic services to Bangalore, opening a new processing centre outside Tamil Nadu.

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

Dangerous side effects from medicines, such as blood clots and heart rhythm disturbances, could potentially be avoided by a ...

Expert and Family Heart Foundation Ambassador Discuss the Genetic Risks of High Lipoprotein(a) and How Individuals Can Access Free At-Home Screening & Support Through Cholesterol Connect Program NEW ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Researchers at Swedish institutions, including Karolinska Institutet, have identified gene variants that increase the risk of ...

BACKGROUND: Shared genetic and lifestyle risk factors may underlie the development of both coronary artery disease (CAD) and ...